Healthy Clinical Trial
— BrainSTIMOfficial title:
Leveraging Behavioral State to Enhance Specificity of Non-invasive Brain Stimulation on Motor Circuits
Repetitive transcranial magnetic stimulation (rTMS) is a powerful tool to non-invasively modulate brain circuits, brain plasticity, and behavior. This proposal will test the hypothesis that controlling behavioral state during focal multi-day rTMS of a brain region involved in grasping movements will enhance the functional specificity of the neuromodulation action among distributed brain regions involved in voluntary motor control and concomitantly improve manual dexterity. Results from this study will be used to optimize rTMS therapy for individuals with neuromotor impairments by controlling behavioral state to improve the efficacy of rTMS treatment. Healthy volunteers that qualify for this study will have motor skill assessments and basic neuromotor testing (using neurophysiology with TMS and functional Magnetic Resonance Imaging (fMRI) scans). Participants will be asked to come in for up to nine sessions that include 1 screening session, 5 consecutive daily rTMS sessions and 3 assessment sessions with resting-state and task-based fMRI, neurophysiology with TMS, and hand motor tasks over the course of 3-4 weeks.
Status | Recruiting |
Enrollment | 65 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Women of child bearing age cannot be pregnant or trying to become pregnant - Ability to tolerate small, enclosed spaces without anxiety - Ability and willingness to give informed consent to participate - No history of neurological disorder - Right handed - English speaking Exclusion Criteria: - Are left-handed - Are younger than 18 or older than 50 years old - Women who are pregnant, suspect they are pregnant, or are attempting to become pregnant - Have metal anywhere in the head, excluding the mouth - Have a pacemaker, deep brain stimulator, vagus nerve stimulator or any other medically implanted device - Have cochlear hearing implants - Are taking GABAergic, NDMA-receptor antagonist, or other drug known to influence neural receptors - Have any of the below conditions that would put participants at increased risk of having a seizure: a personal or family history of seizure/epilepsy, taking prescription drugs that lower the threshold for seizures, recent history of excessive alcohol consumption, history of alcohol addiction/dependence, recent history of recreational drug use, history of drug addiction/dependence - Have been diagnosed with any of the following: a stroke, brain hemorrhage, brain tumor, encephalitis, multiple sclerosis, Parkinson's disease or Alzheimer's disease, depression in the past 6 months, attention deficit disorder, schizophrenia, manic depressive (bipolar) disorder, normal pressure hydrocephalus or increased intra-cranial pressure, diabetes requiring insulin treatment, any serious heart disorder or liver disease - Have had a migraine in the past month - MRI specific exclusion criteria: Any relevant history of open-heart surgery, artificial heart valve, brain aneurysm surgery, braces or extensive dental work, cataract surgery or lens implant, or artificial limb or joint. History of foreign metallic object in the body such as bullets, BB's, pellets, shrapnel, or metalwork fragments. Claustrophobia, have uncontrollable shaking, or cannot lie still for one hour. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
University of Michigan | National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage change in the time to complete the nine-hole peg test (9-HPT) to immediate post-intervention | 9-hole peg test is a manual dexterity measure, estimated as the time required to complete the task (seconds) | Baseline and immediate post-intervention (up to 30 min) | |
Primary | Percentage change in amplitude of motor evoked potential (MEP) to immediate post-intervention. | Motor cortical excitability is measured by electromyography using MEPs elicited by TMS | Baseline and immediate post-intervention (up to 60 min) | |
Primary | Change from baseline functional connectivity to PPC stimulation target within the cortical grasping network to immediate post-intervention. | Resting-state connectivity of low frequency BOLD fluctuations for a seed at the PPC | Baseline and immediate post-intervention (up to 60 min during fMRI) | |
Primary | Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in the cortical grasp network to immediate post-intervention. | Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task | Baseline and immediate post-intervention (up to 60 min during fMRI) | |
Secondary | Percentage change in the time to complete the nine-hole peg test (9-HPT) to 1-week post-intervention | 9-hole peg test is a manual dexterity measure, estimated as the time required to complete the task (seconds) | Baseline and 1-week post-intervention (up to 30 min) | |
Secondary | Percentage change in amplitude of motor evoked potential (MEP) to 1-week post-intervention. | Motor cortical excitability is measured by electromyography using MEPs elicited by TMS | Baseline and 1-week post-intervention (up to 60 min) | |
Secondary | Change from baseline functional connectivity to PPC stimulation target within the cortical grasping network to 1-week post-intervention. | Resting-state connectivity of low frequency BOLD fluctuations for a seed at the PPC | Baseline and 1-week post-intervention (up to 60 min during fMRI) | |
Secondary | Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in the cortical grasp network to 1-week post-intervention. | Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task | Baseline and 1-week post-intervention (up to 60 min during fMRI) | |
Secondary | Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in whole brain to immediate post-intervention. | Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task | Baseline and immediate-intervention (up to 60 min during fMRI) | |
Secondary | Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in whole brain to 1-week post-intervention. | Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task | Baseline and 1-week post-intervention (up to 60 min during fMRI) | |
Secondary | Percentage change in accuracy to precision force-tracking task to immediate post-intervention | Squared distance (error) from the cursor to the target in precision force-tracking task, estimated as the root mean squared error (RMSE) | Baseline and immediate post-intervention (up to 60 min during fMRI and outside scanner) | |
Secondary | Percentage change in accuracy to precision force-tracking task to 1-week post-intervention | Squared distance (error) from the cursor to the target in precision force-tracking task, estimated as the root mean squared error (RMSE) | Baseline and 1-week post-intervention (up to 60 min during fMRI and outside scanner) | |
Secondary | Percentage change in the mean choice reaction time to immediate post-intervention | Mean reaction time for subjects responding in the 2-choice reaction time control task, for correct responses | Baseline and immediate post-intervention (up to 30 min) | |
Secondary | Percentage change in the mean choice reaction time to 1-week post-intervention | Mean reaction time for subjects responding in the 2-choice reaction time control task, for correct responses | Baseline and 1-week post-intervention (up to 30 min) | |
Secondary | Percentage change in the normalized motor evoked potential (MEP) size to immediate post-intervention. | Parietal-motor functional connectivity is measured by electromyography using MEPs elicited by dual-site TMS, while subjects perform an object-directed grasp/subjects are at rest | Baseline and immediate post-intervention (up to 60 min) | |
Secondary | Percentage change in the normalized motor evoked potential (MEP) size to 1-week post-intervention. | Parietal-motor functional connectivity is measured by electromyography using MEPs elicited by dual-site TMS, while subjects perform an object-directed grasp/subjects are at rest | Baseline and 1-week post-intervention (up to 60 min) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |